← Back to Screener
Matinas BioPharma Holdings, Inc. (MTNB)
Price$0.79
Value ScoreA
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-2.73%
Price vs S&P 500 (4W)23.66%
VGM Score69.76
Market Capitalization$5.05M
All Metrics
Book Value / Share (Quarterly)$0.47
P/TBV (Annual)1.46x
Cash Flow / Share (Quarterly)$-1.03
Price vs S&P 500 (YTD)26.48%
Net Profit Margin (TTM)-479.27%
EPS (TTM)$-1.62
10-Day Avg Trading Volume0.08M
EPS Excl Extra (TTM)$-1.62
EPS (Annual)$-4.98
ROI (Annual)-318.80%
Net Profit Margin (5Y Avg)-21226.03%
Cash / Share (Quarterly)$0.37
ROA (Last FY)-191.84%
EBITD / Share (TTM)$-0.89
ROE (5Y Avg)-115.12%
Operating Margin (TTM)-483.12%
Cash Flow / Share (Annual)$-1.09
P/B Ratio1.67x
P/B Ratio (Quarterly)1.06x
Net Income / Employee (Annual)$-12,125,500
EV / Revenue (TTM)0.62x
Net Interest Coverage (TTM)-459.25x
ROA (TTM)-92.02%
EPS Incl Extra (Annual)$-4.98
Current Ratio (Annual)2.79x
Quick Ratio (Quarterly)1.15x
3-Month Avg Trading Volume0.11M
52-Week Price Return-10.05%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.12
P/S Ratio (Annual)4.61x
Asset Turnover (Annual)0.04x
52-Week High$3.09
Operating Margin (5Y Avg)-21513.86%
EPS Excl Extra (Annual)$-4.98
Tangible BV CAGR (5Y)-46.87%
26-Week Price Return5.20%
Quick Ratio (Annual)2.77x
13-Week Price Return36.98%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)1.32x
Enterprise Value$2.66M
Asset Turnover (TTM)0.09x
Book Value / Share Growth (5Y)18.81%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-2093.25%
Cash / Share (Annual)$0.62
3-Month Return Std Dev83.69%
Net Income / Employee (TTM)$-4,344,500
ROE (Last FY)-319.51%
EPS Basic Excl Extra (Annual)$-4.98
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.62
ROI (TTM)-137.17%
P/S Ratio (TTM)1.18x
Pretax Margin (5Y Avg)-21226.03%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.40
Price vs S&P 500 (52W)-34.42%
Year-to-Date Return34.64%
5-Day Price Return-9.52%
EPS Normalized (Annual)$-4.98
ROA (5Y Avg)-79.94%
Net Profit Margin (Annual)-2093.25%
Month-to-Date Return-2.59%
Cash Flow / Share (TTM)$-0.10
EBITD / Share (Annual)$-4.98
Operating Margin (Annual)-2124.27%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-114.93%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.62
P/TBV (Quarterly)4.20x
P/B Ratio (Annual)0.78x
Pretax Margin (TTM)-479.27%
Book Value / Share (Annual)$0.75
Price vs S&P 500 (13W)28.72%
Beta1.67x
Revenue / Share (TTM)$0.00
ROE (TTM)-137.45%
52-Week Low$0.48
vGradeA
mGradeC
vgmGradeB
Show chart for
Analyst Recommendations
Jun 2025
Jul 2025
Aug 2025
Oct 2025
2.29
2.29
2.29
2.29
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
MTNBMatinas BioPharma Holdings, Inc. | A | — | C | $0.79 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Matinas BioPharma is a clinical-stage biopharmaceutical company developing novel pharmaceutical treatments. The company's pipeline includes MAT2203, MAT2501, and other therapeutic candidates. The company focuses on identifying and advancing innovative drug candidates through clinical development.